Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group

This study was designed to assess the efficacy and safety of intravenous dofetilide in acute termination of atrial fibrillation (AF) and flutter (AFL). Dofetilide, an investigational class III antiarrhythmic agent, selectively inhibits the rapid component of the delayed rectifier potassium current,...

Full description

Saved in:
Bibliographic Details
Published in:The American heart journal 1999-06, Vol.137 (6), p.1062
Main Authors: Nørgaard, B L, Wachtell, K, Christensen, P D, Madsen, B, Johansen, J B, Christiansen, E H, Graff, O, Simonsen, E H
Format: Article
Language:English
Subjects:
Aged
Anti-Arrhythmia Agents - administration & dosage
Anti-Arrhythmia Agents - adverse effects
Anti-Arrhythmia Agents - pharmacokinetics
Atrial Fibrillation - blood
Atrial Fibrillation - drug therapy
Atrial Fibrillation - physiopathology
Atrial Flutter - blood
Atrial Flutter - drug therapy
Atrial Flutter - physiopathology
Denmark
Double-Blind Method
Female
Hemodynamics - drug effects
Humans
Infusions, Intravenous
Male
Middle Aged
Phenethylamines - administration & dosage
Phenethylamines - adverse effects
Phenethylamines - pharmacokinetics
Placebos
Potassium Channel Blockers
Prospective Studies
Safety
Sulfonamides - administration & dosage
Sulfonamides - adverse effects
Sulfonamides - pharmacokinetics
Time Factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study was designed to assess the efficacy and safety of intravenous dofetilide in acute termination of atrial fibrillation (AF) and flutter (AFL). Dofetilide, an investigational class III antiarrhythmic agent, selectively inhibits the rapid component of the delayed rectifier potassium current, thus prolonging the effective refractory period and duration of the action potential. Dofetilide can be administered intravenously and has a rapid onset of electrophysiologic action. Ninety-six patients with AF (n = 79) or AFL (n = 17) with a median arrhythmia duration of 62 days (range 1 to 180) were randomized to placebo (n = 30) or 8 micrograms/kg IV dofetilide (n = 66) over 30 minutes. Conversion was defined as termination of the atrial arrhythmia within 3 hours from the start of infusion. The conversion rate was 30.3% after dofetilide and 3.3% after placebo (P
ISSN:0002-8703